RxDoctor Payments Data

Leslie Gorrell

Family · Atlanta, GANPI 1669972527

Payments from drug & device makers

$5,436in general payments, 2019–2025

Across 114 payments — averaging $47.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$2K
  • Boston Scientific$1K
  • Teleflex LLC$891
  • Astellas Pharma US Inc$255
  • Sumitomo Pharma America, Inc.$250
  • Endo Pharmaceuticals Inc.$197
  • plus $1K from 21 others

What the payments were for

  • Travel & lodging$2,20241%
  • Food & beverage$3,23459%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,436 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$105,823
Medicare patients
548
Services billed
1,257

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron174$136,780
MyrbetriqMirabegron120$92,914
Estradiol118$9,506
Solifenacin Succinate79$3,685
Testosterone29$2,763
Cephalexin136$2,701
Methenamine Hippurate24$2,448
Tamsulosin Hcl137$1,940
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst161$1,768
Silodosin15$911
Testosterone Cypionate21$882
Alfuzosin Hcl ErAlfuzosin Hcl37$854
NitrofurantoinNitrofurantoin Macrocrystal33$726
Oxybutynin Chloride ErOxybutynin Chloride43$553
Finasteride40$371

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$250$136,780174 claims
Astellas Pharma US IncMyrbetriq$255$92,914120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →